CXCL11 negatively regulated by MED19 favours antitumour immune infiltration in breast cancer. (February 2023)

• Record Type: Journal Article
• Authors: Zhang, Xiufen; Wu, Junqiang; Hu, Caixia; Zheng, Xiaoyuan; Guo, Zijian; Li, Lihua
• Is Part Of: Cytokine. Volume 162(2023)
• Publication Date: 2023-02
• Subjects: CXCL11 -- MED19 -- Breast cancer -- Immune infiltration; Cytokines -- Periodicals; 571.844
• DOI: 10.1016/j.cyto.2022.156106
• Languages: English
• ISSNs: 1043-4666

Abstract

Highlights: Inhibiting MED19, a tumor-promotor, caused CXCL11 upregulation in breast cancer. The relative positive regulation on cytokine pathways were enriched after MED19 knockdown. High CXCL11 level facilitated antitumor immune cell infiltration. CXCL11 level was associated with the sensitivity to pharmacotherapy by prediction. Abstract: Background: Through microarray results, we found that the C-X-C motif chemokine ligand 11 (CXCL11) was negatively regulated by mediator complex subunit 19 (MED19), a protumour factor. However, the biological role and potential mechanism of CXCL11 need to be explored in breast cancer (BRCA). Methods: The BRCA dataset was obtained from the Cancer Genome Atlas (TCGA) dataset. Our microarray data and the BRCA dataset of TCGA were analysed and visualized using the R software package. The mRNA and protein levels were measured by qRT-PCR and western blotting. Results: Inhibition of MED19 in MDA-MB-231 cells caused CXCL11 upregulation. The relative positive regulation of cytokine pathways was enriched after MED19 knockdown. High CXCL11 was determined to be positively correlated with immune response activation, increased antitumour immune cell infiltration, immune checkpoint molecule expression, and enhanced sensitivity to immunotherapy and chemotherapy. Collectively, CXCL11 promoted antitumour immunity and was regulated by MED19 in BRCA. Clarifying the prognostic value and underlying mechanism of CXCL11 in BRCA could provide a theoretical basis to find new diagnostic and therapeutic targets.